Contact Us

Free ParentSmart Healthline^TM

Caring pediatric nurses are available 24/7 to help answer your health questions.

720-777-0123

Send Postal Mail To:

Children’s Hospital Colorado
Anschutz Medical Campus
13123 East 16th Avenue
Aurora, CO 80045

Looking for a different location?

Locations

Emergency Locations

Urgent Care Locations

Locations Near You

See All Locations

Infectious Disease

Dan Olson, MD

Specialties:: Infectious Disease - Pediatric, Pediatrics

720-777-6981

Get to know his background

Clinical interests

My clinical interests include the management of infections in children

Undergraduate 2002

Grinnell College (IA)

Medical School 2007

Michigan State University College of Human Medicine

Internship 2008

University of Wisconsin (Madison) Program

Residency 2010

University of Wisconsin (Madison) Program, Pediatrics

Fellowship 2015

University of Colorado (Children's Hospital Colorado) Program, Pediatric Infectious Diseases

Anschutz Medical Campus, Aurora

13123 East 16th Avenue
Aurora, CO 80045

View Map

Student Traineeship Award 2010

Cystic Fibrosis Foundation

Fogarty International Clinical Research Fellowship Award 2010

Fogarty International Center

Resident Teaching Award 2010

Awarded to one resident each year in each department by the UW school of medicine
University of Wisconsin School of Medicine

Research and grants

Website: http://www.ncbi.nlm.nih.gov/sites/myncbi/16WzmM_hEoDA1/bibliography/41093132/public/?sort=date&direction=ascending

For Patients:
My research interests are focused on how to measure the effectiveness of vaccines in the real world. We are developing new strategies to monitor how well vaccines work at our University of Colorado research site in Guatemala.

For Referring Providers:
My research interests include using new technologies for disease surveillance and vaccine effectiveness. I am currently working at the University of Colorado Trifinio Research Site in rural Guatemala to validate new surveillance systems for dengue and norovirus. These surveillance systems use smartphones for symptom reporting. We will also participate in a Phase III dengue vaccine trial.